Automated Breast Ultrasound Systems Market By Product Type (Automated Breast Ultrasound Systems (ABUS), Automated Breast Volume Scanner (ABVS)), By Technology (3D Automated Breast Ultrasound, Conventional Automated Ultrasound), By Application (Screening, Diagnosis), By End-User (Hospitals, Diagnostic Imaging Centers, Specialty Clinics), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Automated Breast Ultrasound Systems Market was valued at USD 2.4 billion in 2024-e and will surpass USD 4.2 billion by 2030; growing at a CAGR of 9.8% during 2025 - 2030.

The automated breast ultrasound systems (ABUS) market is experiencing rapid growth due to increasing breast cancer prevalence, advancements in imaging technology, and growing awareness about early cancer detection. Traditional mammography often struggles to detect tumors in women with dense breast tissue, driving the adoption of automated ultrasound systems as a complementary screening tool. ABUS and automated breast volume scanners (ABVS) offer enhanced imaging accuracy, standardized screening protocols, and improved workflow efficiency for radiologists, making them a preferred choice in breast cancer diagnostics.

The integration of artificial intelligence (AI) in automated ultrasound systems has further boosted market expansion. AI-driven algorithms assist in image analysis, lesion detection, and reporting efficiency, reducing diagnostic errors and improving patient outcomes. Additionally, rising government initiatives promoting breast cancer screening programs and the increasing availability of reimbursement policies are fueling market growth. With continuous innovations in ultrasound imaging and the rising need for non-invasive diagnostic tools, the ABUS market is expected to witness sustained demand.

Automated Breast Ultrasound Systems (ABUS) Hold the Largest Share Owing to Their Widespread Adoption in Dense Breast Screening

Automated breast ultrasound systems (ABUS) dominate the product segment due to their significant role in improving breast cancer detection, particularly in women with dense breast tissue. Unlike traditional mammography, which has limitations in dense breasts, ABUS provides consistent and reproducible 3D imaging, allowing radiologists to detect tumors with greater accuracy. These systems reduce operator dependency and ensure standardized imaging, leading to their widespread adoption in hospitals and imaging centers.

Regulatory approvals, such as the FDA’s endorsement of ABUS for breast cancer screening, have further propelled their market growth. Many healthcare facilities are integrating ABUS into their routine screening programs to enhance early detection rates. Moreover, ongoing advancements in ultrasound technology, including AI-powered image interpretation and automation features, are strengthening the dominance of ABUS in the market. As awareness about breast density-related cancer risks increases, the demand for ABUS is expected to rise further.

3D Automated Breast Ultrasound Technology Leads the Market Due to Superior Imaging Capabilities and High Diagnostic Accuracy

3D automated breast ultrasound technology holds the largest share in the market due to its ability to provide detailed volumetric imaging, enhancing lesion characterization and early cancer detection. Unlike conventional automated ultrasound, 3D ABUS captures entire breast volumes and reconstructs high-resolution images, enabling radiologists to analyze multiple imaging planes for better diagnosis. This technology minimizes the limitations of handheld ultrasound by offering greater consistency and reducing human error.

The growing preference for 3D ABUS is also driven by its integration with AI-based image processing tools, which further enhance diagnostic accuracy and efficiency. Hospitals and diagnostic centers increasingly favor 3D ABUS as part of comprehensive breast screening programs, particularly for high-risk patient groups. As technological advancements continue to improve imaging clarity, workflow automation, and user-friendliness, 3D ABUS is expected to maintain its leading position in the market.

Screening is the Largest Application Segment Due to Rising Breast Cancer Awareness and Government-Led Screening Programs

The screening segment dominates the ABUS market, driven by the increasing focus on early breast cancer detection and government initiatives promoting nationwide screening programs. With breast cancer being one of the leading causes of cancer-related deaths globally, early detection through regular screening is crucial in improving survival rates. Automated breast ultrasound systems are widely used in population-based screening programs, especially for women with dense breasts, where traditional mammography may not be as effective.

Many countries have introduced policies mandating supplemental breast ultrasound screening for women with dense breast tissue, further driving demand for ABUS. Additionally, advancements in automated imaging technology have improved the speed and accuracy of screening procedures, making them more efficient for large-scale adoption. As healthcare systems continue to emphasize preventive diagnostics, the demand for ABUS in breast cancer screening is expected to grow significantly.

Hospitals Are the Leading End-User Due to High Patient Volume and Adoption of Advanced Diagnostic Technologies

Hospitals hold the largest share in the end-user segment, owing to their role as primary healthcare providers for breast cancer diagnosis and treatment. With a high volume of patients undergoing routine breast cancer screenings and diagnostic evaluations, hospitals are increasingly integrating automated ultrasound systems into their radiology departments. The availability of multidisciplinary teams, access to cutting-edge imaging technologies, and reimbursement policies further support hospital adoption of ABUS.

Moreover, hospitals are at the forefront of implementing AI-driven imaging solutions and automated diagnostic tools, enhancing workflow efficiency and diagnostic accuracy. Many hospitals also collaborate with government screening programs and research institutions to expand breast cancer screening services. As healthcare infrastructure continues to advance and hospitals invest in state-of-the-art imaging modalities, their dominance in the ABUS market is expected to persist.

North America Leads the Market Due to Strong Healthcare Infrastructure and High Awareness of Breast Cancer Screening

North America is the largest regional market for automated breast ultrasound systems, driven by well-established healthcare infrastructure, high breast cancer awareness, and strong government support for screening programs. The region has witnessed a growing adoption of ABUS in hospitals, diagnostic centers, and specialty clinics due to its proven efficacy in dense breast imaging. The presence of major market players, continuous technological advancements, and favorable reimbursement policies further contribute to market growth.

The United States, in particular, has stringent breast cancer screening guidelines and a high number of regulatory-approved ABUS systems, supporting widespread adoption. Additionally, increasing investments in AI-powered imaging solutions and research collaborations between healthcare institutions and technology firms are propelling market expansion. As the demand for accurate and efficient breast cancer diagnostics continues to rise, North America is expected to maintain its leading position in the ABUS market.

Competitive Landscape and Key Players

The automated breast ultrasound systems market is highly competitive, with key players such as GE Healthcare, Siemens Healthineers, Canon Medical Systems, and Hologic Inc. leading the industry. These companies focus on continuous innovation, AI integration, and strategic partnerships to strengthen their market presence. Investments in research and development for enhanced imaging technologies, improved workflow automation, and regulatory approvals are key strategies adopted by market leaders.

The growing focus on personalized diagnostics, cloud-based imaging solutions, and AI-powered radiology tools is reshaping the competitive landscape. Emerging players are entering the market with cost-effective and technologically advanced solutions, intensifying competition. As healthcare providers prioritize efficiency, accuracy, and patient-centered care, companies that offer innovative, high-performance ABUS solutions will continue to gain a competitive edge.

List of Leading Companies:

• GE HealthCare
• Siemens Healthineers
• Canon Medical Systems Corporation
• Koninklijke Philips N.V.
• Hologic, Inc.
• Hitachi Ltd.
• SonoCiné Inc.
• Seno Medical Instruments
• Delphinus Medical Technologies, Inc.
• iVu Imaging Corporation
• Fukuda Denshi Co., Ltd.
• SuperSonic Imagine
• QT Imaging Inc.
• MetriTrack, Inc.
• NovaSignal Corp.

 Recent Developments:

• In January 2025, GE HealthCare introduced a next-generation AI-powered ABUS for enhanced breast cancer screening.
• In December 2024, Siemens Healthineers received FDA approval for its latest 3D breast ultrasound system.
• In November 2024, Hologic announced a strategic partnership to integrate AI-driven diagnostics into ABUS technology.
• In October 2024, Canon Medical Systems launched an automated breast ultrasound scanner with improved image resolution.
• In September 2024, Delphinus Medical Technologies expanded its ABUS product line to improve dense breast tissue detection.

Report Scope: